Who Paid My Doc
Phillip Horne
Orthopaedic Surgery of the Spine Cary, NC Medical Doctor
NPI 1073757720 CMS profile 1020458
160 MacGregor Pines Dr Ste 301, Cary, NC 27511
General payments
$45,100
Research payments
$0
Ownership & investment interest
$180,538
Research they led as principal investigator
$159,340
Through program year 2025, Phillip Horne of Cary, NC is reported in the CMS Open Payments database as having received $45,100 across 115 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $159,340 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $180,538 across 1 holding.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 68th percentile of Orthopaedic Surgery of the Spine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
8 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $5,424 | 13 | |
| 2024 | General | $6,908 | 47 | |
| 2023 | General | $3,427 | 12 | |
| 2022 | General | $7,843 | 9 | |
| 2021 | General | $17,810 | 15 | |
| 2020 | General | $1,440 | 3 | |
| 2019 | General | $2,247 | 16 | |
| 2025 | Ownership | $180,538 | 1 |
Beside peers
- Phillip Horne
- Orthopaedic Surgery of the Spine median
- Middle half of Orthopaedic Surgery of the Spine
- National median
In program year 2025, general payments to Phillip Horne were reported at $5,424. Among 1,704 Orthopaedic Surgery of the Spine profiles paid that year, the median was $2,061 and the middle half received between $347 and $14,651.
Show as a table
| Year | Phillip Horne | Orthopaedic Surgery of the Spine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $2,247 | $2,106 | $337–$18,608 | $163 |
| 2020 | $1,440 | $1,213 | $156–$15,082 | $114 |
| 2021 | $17,810 | $1,834 | $271–$15,617 | $132 |
| 2022 | $7,843 | $2,015 | $320–$17,036 | $149 |
| 2023 | $3,427 | $1,925 | $336–$14,599 | $160 |
| 2024 | $6,908 | $2,110 | $341–$12,483 | $164 |
| 2025 | $5,424 | $2,061 | $347–$14,651 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 12 drugsPart D claims
522
Drug cost
$4,001
Branded share of claims
12.5%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Gabapentin | Generic | 78 | $746 | |
| Oxycodone Hcl | Generic | 87 | $701 | |
| Pregabalin | Generic | 36 | $618 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 65 | $494 | |
| Methylprednisolone | Generic | 56 | $346 | |
| Tizanidine Hcl | Generic | 38 | $275 | |
| Methocarbamol | Generic | 25 | $244 | |
| Diclofenac Sodium | Generic | 16 | $174 | |
| Meloxicam | Generic | 58 | $155 | |
| Celecoxib | Generic | 12 | $155 |
The 10 drugs with the highest cost, of 12 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 48 billing codesPaid by Medicare
$142,587
Medicare patients
139
Services billed
789
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 75% | |
| Depression | 38% | |
| Diabetes | 32% | |
| Ischemic heart disease | 32% | |
| Chronic kidney disease | 29% | |
| Osteoporosis | 26% | |
| Heart failure | 15% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
115 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Orthopaedic Surgery of the Spine in North Carolina
Peter Passias
Orthopaedic Surgery of the Spine · Durham, NC
Daniel Williams
Orthopaedic Surgery of the Spine · Pinehurst, NC
Alexander Lemons
Orthopaedic Surgery of the Spine · Pinehurst, NC
Daniel Cavanaugh
Orthopaedic Surgery of the Spine · Chapel Hill, NC
Olumide Danisa
Orthopaedic Surgery of the Spine · Durham, NC
Conor Regan
Orthopaedic Surgery of the Spine · Raleigh, NC
Related records
Orthopaedic Surgery of the Spine in North Carolina
Practitioners in the same specialty and state, ranked by reported value.
All Orthopaedic Surgery of the Spine
Everyone recorded under this specialty, nationwide.
Doctors in North Carolina
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.